Reporting owner · CIK 0002033974

Agarwal Arjun

SEC Form 4 history for the last 180 days across 1 company, 19 transactions and 3 filings.

SVPSenior Vice President, FinanceOruka Therapeutics, Inc.
Open-market transaction mix0% buys0 buys · 11 sales

Period: Last 180 days

Trade dates in this period: Sep 21, 2026 – Nov 12, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings3Form 4 records
Buying$00 purchases
Selling$1.91M11 sales
Net value−$1.91MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Agarwal Arjun transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$10.7kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$102kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$720kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$83.3kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$82.6kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$51.0kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$50.1kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$107kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$16.6kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$160kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$170kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$459kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$50.1kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$107kView disclosure →
ORKAOruka Therapeutics, Inc.
Senior Vice President
SVP
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$51.0kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at Oruka Therapeutics, Inc. on Nov 12, 2026 valued at $10,700.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 3 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Sep 202601$0$51,034.75−$51,034.75
Oct 202604$0$805,888.88−$805,888.88
Nov 202606$0$1,049,657.83−$1,049,657.83

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$173k
Median P/S size$83.3k
Direct19
Indirect0
Nov 12, 2026exercise

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

15 observations · Sep 21, 2026 – Nov 12, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 12, 202614,219 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Sep 21, 202614,219Sep 21, 2026View transaction
Oct 12, 202622,760Oct 13, 2026View transaction
Oct 12, 202624,218Oct 13, 2026View transaction
Oct 12, 202618,477Oct 13, 2026View transaction
Oct 12, 202616,377Oct 13, 2026View transaction
Oct 12, 202614,419Oct 13, 2026View transaction
Oct 12, 202614,219Oct 13, 2026View transaction
Nov 12, 202622,761Nov 13, 2026View transaction
Nov 12, 202624,219Nov 13, 2026View transaction
Nov 12, 202623,719Nov 13, 2026View transaction
Nov 12, 202622,918Nov 13, 2026View transaction
Nov 12, 202622,119Nov 13, 2026View transaction
Nov 12, 202615,277Nov 13, 2026View transaction
Nov 12, 202614,319Nov 13, 2026View transaction
Nov 12, 202614,219Nov 13, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Agarwal Arjun Insider Activity FAQ

SEC Form 4 context

Who is Agarwal Arjun?

Agarwal Arjun is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002033974.

Which companies has Agarwal Arjun reported transactions for?

Oruka Therapeutics, Inc.

When was Agarwal Arjun's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Agarwal Arjun's latest insider sale?

The insider reported a sale at Oruka Therapeutics, Inc. on Nov 12, 2026 valued at $10,700.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.